Who is sponsoring NCT03111212?

NCT03111212 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03111212?

Interventions in NCT03111212: Iloprost, control.

What condition does NCT03111212 study?

NCT03111212 studies Respiratory Distress Syndrome, Adult.

Is NCT03111212 still recruiting?

NCT03111212 is currently completed. Last updated 30 December 2021.

Last reviewed 2021-12-30 · How we verify

NCT03111212: ThIlo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iloprost in Acute Respiratory Distress Syndrome

Completed Phase 3 Last updated 30 December 2021

What this trial tests

Phase 3 trial testing Iloprost in Respiratory Distress Syndrome, Adult in 150 participants. Completed in 14 August 2021.

Timeline

25 June 2019

Primary endpoint
14 May 2021

14 August 2021

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	25 June 2019
Primary completion	14 May 2021
Estimated completion	14 August 2021
Sites	1 location across Germany

Drugs / interventions tested

Iloprost — full drug profile →
control

Conditions studied

Respiratory Distress Syndrome, Adult — all drugs for Respiratory Distress Syndrome, Adult →

Sponsor

University Hospital Tuebingen

Who can join

18 and older, any sex, with Respiratory Distress Syndrome, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics.
Pokharel MD, Garcia-Flores A, Marciano D, Franco MC, et al · · 2024 · cited 73× · PMID 38295575 · DOI 10.1016/j.redox.2024.103049
Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies.
Battaglini D, Fazzini B, Silva PL, Cruz FF, et al · · 2023 · cited 48× · PMID 36835919 · DOI 10.3390/jcm12041381
Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome.
Gierhardt M, Pak O, Walmrath D, Seeger W, et al · · 2021 · cited 26× · PMID 34526314 · DOI 10.1183/16000617.0059-2021
Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.
Hussain M, Xu C, Ahmad M, Majeed A, et al · · 2018 · cited 24× · PMID 29484641 · DOI 10.1002/cpt.1034
Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study.
Sen'kova AV, Savin IA, Brenner EV, Zenkova MA, et al · · 2021 · cited 10× · PMID 34807957 · DOI 10.1371/journal.pone.0260450
Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study.
Haeberle H, Prohaska S, Martus P, Straub A, et al · · 2020 · cited 10× · PMID 32131881 · DOI 10.1186/s13063-020-4163-0
Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial.
Haeberle HA, Calov S, Martus P, Serna-Higuita LM, et al · · 2023 · cited 7× · PMID 36805707 · DOI 10.1186/s12931-023-02346-0
COVID-19 does not influence functional status after ARDS therapy.
Bernard A, Serna-Higuita LM, Martus P, Mirakaj V, et al · · 2023 · cited 1× · PMID 36740717 · DOI 10.1186/s13054-023-04330-y

Verify or expand the search:

Other trials of Iloprost

Trials testing the same drug.

NCT05411107 — Oral Iloprost for the Prevention of Lung Cancer In Former Smokers · Phase 2 · withdrawn
NCT06319274 — Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure · Phase 2 · recruiting
NCT04420741 — Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure · Phase 2 · completed
NCT04123444 — Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure · Phase 2, PHASE3 · completed
NCT03903939 — Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure · Phase 2 · completed

Other recruiting trials for Respiratory Distress Syndrome, Adult

Currently open trials in the same condition.

NCT06203405 — The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Ra · NA · recruiting
NCT04545424 — Trial of Therapeutic Hypothermia in Patients With ARDS · Phase 2 · recruiting
NCT03368092 — Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma · Phase 3 · recruiting
NCT03709199 — Long Term Follow up of Children Enrolled in the REDvent Study · active not recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03111212 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 30 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03111212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing